Recent research is challenging long-held assumptions about the safety profile of a commonly used diabetes medication. In a study conducted by investigators at Mass General Brigham, new evidence suggests that glipizide—a sulfonylurea widely prescribed for type 2 diabetes—is associated with a higher incidence of heart-related conditions compared to another class of diabetes drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors. This emerging data underscores the complex interplay between glycemic control and cardiovascular health and invites a reexamination of treatment strategies for millions of patients living with type 2 diabetes.
Background and Context
Type 2 diabetes is a chronic condition that impairs the body’s ability to regulate blood sugar, often resulting in elevated blood glucose levels that can lead to serious complications over time. Among these complications, cardiovascular diseases such as heart failure, stroke, and cardiac arrest are particularly concerning. For decades, clinicians have relied on a range of medications—notably metformin, sulfonylureas, and DPP-4 inhibitors—to help patients manage their blood sugar. Metformin typically serves as the therapy’s cornerstone, while sulfonylureas like glipizide, glimepiride, and glyburide have been popular due to their affordability and proven efficacy in lowering blood sugar levels.
